Tumor necrosis factor-like weak inducer of apoptosis and its potential roles in lupus nephritis

Inflammation Research

Volumn 61, Issue 4, 2012, Pages 277-284

  Liu, Zhi Chun ^a   Zhou, Qiao Ling ^b  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Fibroblast growth factor inducible 14; Keywords tumor necrosis factor like weak inducer of apoptosis; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

CHEMOKINE; CXCL1 CHEMOKINE; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; PROTEIN KINASE B; RANTES; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; CELL PROLIFERATION; DENDRITIC CELL; HUMAN; IMMUNOGLOBULIN DEPOSITION; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TWEAK GENE;

ANIMALS; HUMANS; LUPUS NEPHRITIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTORS;

EID: 84863112185     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-011-0420-8     Document Type: Review

References (70)

1. Chicheportiche Y, Bourdon PR, Xu H, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem. 1997;272(51):32401-10.
2. Desplat-Jego S, Creidy R, Varriale S, et al. Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol. 2005;117:15-23.
3. Zhao Z, Burkly LC, Campbell S, et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol. 2007;179:7949-58.
4. Campbell S, Michaelson J, Burkly L, et al. The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci. 2004;9:2273-84.
5. Chen T, Guo ZP, Li MM, et al. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK), an important mediator of endothelial inflammation, is associated with the pathogenesis of Henoch-Schonlein purpura. Clin Exp Immunol. 2011;166(1): 64-71.
6. Sanz AB, Sanchez-Nino MD, Izquierdo MC, et al. TWEAK activates the non-canonical NFkB pathway in murine renal tubular cells: modulation of CCL21. PLoS ONE. 2010;5:e8955.
7. Sanz1 AB, Sánchez Sánchez-Nino1 MaD, et al. The facilitator in acute kidney injury: TWEAK. Nefrología. 2008;6:587-592.
8. Kamata K, Kamijo S, Nakajima A, et al. Involvement of TNFlike weak inducer of apoptosis in the pathogenesis of collageninduced arthritis. J Immunol. 2006;177:6433-9.
9. Zheng TS, Burkly LC. No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies. J Leukoc Biol. 2008;84:338-47.
10. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev. 2003;14:241-9.
11. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008; 7:411-4.
12. Kaplan MJ, Lewis EE, Shelden EA, et al. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol. 2002;169: 6020-9.
13. Kaptein A, Jansen M, Dilaver G, et al. Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMP (DR3). FEBS Lett. 2000;485:135-41.
14. Bossen C, Ingold K, Tardivel A, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem. 2006;281:13946-71.
15. Phillips TA, Ni J, Hunt JS. Death-inducing tumour necrosis factor (TNF) superfamily ligands and receptors are transcribed in human placentae, cytotrophoblasts, placental macrophages and placental cell lines. Placenta. 2001;22:663-72.
16. Marsters SA, Sheridan JP, Pitti RM, Brush J, Goddard A, Ashkenazi A. Identification of a ligand for the death-domaincontaining receptor Apo3. Curr Biol. 1998;8:525-8.
17. Pradet-Balade B, Medema JP, Lopez-Fraga M, et al. An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. EMBO J. 2002;21: 5711-20.
18. Semov A, Semova N, Lacelle C, et al. Alterations in TNF- and IL-related gene expression in space-flown WI-38 human fibroblasts. FASEB J. 2002;16:899-901.
19. Scholzke MN, Rottinger A, Murikinati S, et al. TWEAK regulates proliferation and differentiation of adult neural progenitor cells. Mol Cell Neurosci. 2011;46(1):325-32.
20. Munoz-Garcia B, Madrigal-Matute J, Moreno JA, et al. TWEAKFn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovasc Res. 2011;89(1): 225-33.
21. Feng SY, Guo Y, Factor VM, et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol. 2000;156:1253-61.
22. Gao HX, Campbell SR, Burkly LC, et al. TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine. 2009;46:24-35.
23. Campbell S, Burkly LC, Gao HX, Browning B, et al. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol. 2006;176:1889-98.
24. Wiley SR, Cassiano L, Lofton T, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 2001;15:837-46.
25. Justo P, Sanz AB, Sanchez-Nino MD, Winkles JA, Lorz C, Egido J, Ortiz A. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int. 2006;70:1750-8.
26. Kessler D, Dethlefsen S, Haase I, et al. Fibroblasts in mechanically stressed collagen lattices assume a "synthetic" phenotype. J Biol Chem. 2001;276:36575-85.
27. Waldman M, Madaio MP. Pathogenic autoantibodies in lupus nephritis. Lupus. 2005;14:19-24.
28. Ortiz A, Sanz AB, García BM, et al. Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor. 2009;20:251-8.
29. Lu J, Kwan BC, Lai FM, et al. Gene expression of TWEAK/Fn14 and IP-10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis. Nephrology. 2011;16(4):426-32.
30. Chicheportiche Y, Fossati-Jimack L, Moll S, Ibnou-Zekri N, Izui S. Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem Biophys Res Commun. 2000;279:162-5.
31. Schwartz N, Rubinstein T, Burkly LC et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthr Res Ther. 2009;11:143-53.
32. Gao H-X, Campbell SR, Burkly LC, et al. TNF-like Weak Inducer of Apoptosis (TWEAK) induces potent inflammatory and proliferative effects in human kidney cells. Cytokine. 2009;46: 24-35.
33. Molano A, Lakhani P, Aran A, et al. TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. Immunol Lett. 2009;125:119-28.
34. Bonizzi G, Karin M. The two NFkB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25: 280-8.
35. Lin CH, Wang SC, Ou TT, et al. IjBa promoter polymorphisms in patients with systemic lupus erythematosus. J Clin Immunol. 2007;28:207-13.
36. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107:135-42.
37. Neurath MF, Fuss I, Schurmann G, et al. Cytokine gene transcrition by NF-kappa B family members in patients with inflammatory bowel disease. Ann N Y Acad Sci. 1998;859:149-59.
38. Grimm S, Bauer MK, Baeuerle PA, et al. Bcl-2 down-regulates the activity of transcription factor NF-KB induced upon apoptosis. J Cell Biol. 1996;134:13-23.
39. Silverman N, Maniatis T. NF-kB signaling pathways in mammalian and insect innate immunity. Genes Dev. 2001;15(18):2321-42.
40. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002;2(10):725-34.
41. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104(4):487-501.
42. Zheng L, Sinniah R, Hsu SI. In situ glomerular expression of activated NF-kappaB in human lupus nephritis and other nonproliferative proteinuric glomerulopathy. Virchows Arch. 2006;448(2):172-83.
43. Burgos P, Metz C, Bull P, et al. Increased expression of c-rel, from the NF-kappaB/Rel family, in T cells from patients with systemic lupus erythematosus. J Rheumatol. 2000;27:116-27.
44. Khaled AR, Soares LS, Butfiloski EJ, et al. Inhibition of the p50 (NKkappaB1) subunit of NF-kappaB by phosphorothioate-modified antisense oligodeoxynucleotides reduces NF-kappaB expression and immunoglobulin synthesis in murine B cells. Clin Immunol Immunopathol. 1997;83(3):254-63.
45. Schwaninger M, Inta I, Herrmann O. NF-kappaB signalling in cerebral ischaemia. Biochem Soc Trans. 2006;34(6):1291-4.
46. Roos C, Wicovsky A, Müller N, et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-B pathway. J Immunol. 2010;185:1593-605.
47. Li H, Mittal A, Paul PK, et al. Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor inducing kinase and p38 mitogen-activated protein kinase, a potential role of MMP-9 in myopathy. J Biol Chem. 2009;284:4439-50.
48. Kumar M, Makonchuk DY. TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta-activated kinase 1. J Immunol. 2009;182:2439-48.
49. Harada N, Nakayama M, Nakano H. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2002;299:488-93.
50. Donohue PJ, Richards CM. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol. 2003;23: 594-600.
51. Saas P, Boucraut J, Walker PR, et al. TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia. 2000;32: 102-7.
52. Kumar M, Makonchuk DY, Li H, et al. TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-betaactivated kinase 1. J Immunol. 2009;15:2439-48.
53. Nakashima H, Akahoshi M, Masutani K. Th1/Th2 balance of SLE patients with lupus nephritis. Rinsho Byori. 2006;54: 706-13.
54. Bagavant H, Fu SM. Pathogenesis of kidney disease in systemic lupus erythematosus. Curr Opin Rheumatol. 2009;21:489-94.
55. Kelley VR, Rovin BH. Chemokines: therapeutic targets for autoimmune and inflammatory renal disease. Springer Semin Immunopathol. 2003;24:411-21.
56. Maule WJ. Pathogenesis and future treatments of systemic lupus erythematosus: the role of cytokines and anti-cytokines? Med Technol SA. 2011;25:5-17.
57. Perper SJ, Browning B, Burkly LC, et al. TWEAK is a novel arthritogenic mediator. J Immunol. 2006;177:2610-20.
58. Moore KJ, Wada T, Barbee SD, Kelley VR. Gene transfer of RANTES elicits autoimmune renal injury in MRL-Fas(1pr) mice. Kidney Int. 1998;53:1631-41.
59. Hasegawa H, Kohno M, Sasaki M, et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthr Rheum. 2003;48:2555-66.
60. Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas (lpr) mice. J Exp Med. 1999;190:1813-24.
61. Sugito T, Mineshiba F, Zheng C. Transient TWEAK overexpression leads to a general salivary epithelial cell proliferation. Oral Dis. 2009;15(1):76-81.
62. Kirim S, Tamer T, Saime P, et al. Apoptosis and proliferating cell nuclear antigen in lupus nephritis (class IV) and membranoproliferative glomerulonephritis. Ren Fail. 2005;27:107-13.
63. Lynch CN, Wang YC. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem. 1999;274:8455-9.
64. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastomalike vessels by VEGF withdrawal. Proc Natl Acad Sci USA. 1997;94:8761-6.
65. Donohue PJ, Richards CM, Brown SAN. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arteriosclerosis Thrombosis Vasc Biol. 2003;23:594-600.
66. Ferluga D. Vascular pathology in systemic lupus erythematosus: crossroads of immune complex vasculitis and vasculopathy, thrombotic microangiopathy and arteriosclerosis. Relev Topics Immunopathol. 1999;32:481-3.
67. Nakayama M, Ishidoh K, Kayagaki N, et al. Multiple pathways of TWEAK-induced cell death. J Immunol. 2002;168:734-43.
68. Mannik M, Merrill CE, Stamps LD, Wener MH. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1495-504.
69. Zhang X, Winkles JA, Gongora MC. TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia. J Cereb Blood Flow Metab. 2007;27:534-44.
70. Polavarapu R, Gongora MC, Winkles JA, Yepes M. Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-?B pathway activation. J Neurosci. 2005;25:10094-110.